Base de dados : MEDLINE
Pesquisa : C19.391.693 [Categoria DeCS]
Referências encontradas : 3813 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 382 ir para página                         

  1 / 3813 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29237522
[Au] Autor:Yi LF; Wen HX; Qiu M; Cao XX
[Ad] Endereço:Department of Electrocardiogram, Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430016, China. 380947312@qq.com.
[Ti] Título:[An analysis of cardiac autonomic nerve function in girls with idiopathic central precocious puberty].
[So] Source:Zhongguo Dang Dai Er Ke Za Zhi;19(12):1239-1242, 2017 Dec.
[Is] ISSN:1008-8830
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To investigate the cardiac autonomic nerve function in girls with idiopathic central precocious puberty (ICPP). METHODS: A total of 66 girls with ICPP were enrolled, among whom 36 were obese and 30 were not obese. A total of 68 age-matched healthy girls (normal controls) and 51 girls with simple obesity were enrolled as controls. All the subjects underwent 24-hour ambulatory electrocardiography, and deceleration capacity of heart rate (DC), acceleration capacity of heart rate (AC), and heart rate variability (HRV), and body mass index (BMI) were compared between groups. RESULTS: Compared with the normal control group, the ICPP group had significantly lower DC, standard deviation of normal-to-normal R-R intervals (SDNN), standard deviation of the average normal-to-normal intervals (SDANN), root mean square of successive differences (RMSSD), and high-frequency power (HF) and significantly higher AC and BMI. The ICPP group had significantly lower RMSSD and BMI than the simple obesity group (P<0.05). Compared with the ICPP girls without obesity, those with obesity had significantly lower DC, RMSSD, and HF and significantly higher AC and BMI (P<0.05). CONCLUSIONS: Cardiac autonomic dysfunction is seen in girls with ICPP, especially those with obesity, mainly presenting with reduced vagal tone.
[Mh] Termos MeSH primário: Sistema Nervoso Autônomo/fisiopatologia
Coração/inervação
Puberdade Precoce/fisiopatologia
[Mh] Termos MeSH secundário: Índice de Massa Corporal
Criança
Pré-Escolar
Feminino
Frequência Cardíaca/fisiologia
Seres Humanos
Obesidade/fisiopatologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171215
[St] Status:MEDLINE


  2 / 3813 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28471529
[Au] Autor:Trivisano M; Lucchi C; Rustichelli C; Terracciano A; Cusmai R; Ubertini GM; Giannone G; Bertini ES; Vigevano F; Gecz J; Biagini G; Specchio N
[Ad] Endereço:Neurology Unit, Department of Neuroscience, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy.
[Ti] Título:Reduced steroidogenesis in patients with PCDH19-female limited epilepsy.
[So] Source:Epilepsia;58(6):e91-e95, 2017 06.
[Is] ISSN:1528-1167
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Patients affected by protocadherin 19 (PCDH19)-female limited epilepsy (PCDH19-FE) present a remarkable reduction in allopregnanolone blood levels. However, no information is available on other neuroactive steroids and the steroidogenic response to hormonal stimulation. For this reason, we evaluated allopregnanolone, pregnanolone, and pregnenolone sulfate by liquid chromatographic procedures coupled with electrospray tandem mass spectrometry in 12 unrelated patients and 15 age-matched controls. We also tested cortisol, estradiol, progesterone, and 17OH-progesterone using standard immunoassays. Apart from estradiol and progesterone, all the considered hormones were evaluated in basal condition and after stimulation with adrenocorticotropic hormone (ACTH). A generalized decrease in blood levels of almost all measured neuroactive steroids was found. When considering sexual development, cortisol and pregnenolone sulfate basal levels were significantly reduced in postpubertal girls affected by PCDH19-FE. Of interest, ACTH administration did not recover pregnenolone sulfate serum levels but restored cortisol to control levels. In prepubertal girls with PCDH19-FE, by challenging adrenal function with ACTH we disclosed defects in the production of cortisol, pregnenolone sulfate, and 17OH-progesterone, which were not apparent in basal condition. These findings point to multiple defects in peripheral steroidogenesis associated with and potentially relevant to PCDH19-FE. Some of these defects could be addressed by stimulating adrenocortical activity.
[Mh] Termos MeSH primário: Caderinas/genética
Epilepsia/sangue
Epilepsia/genética
Doenças Genéticas Ligadas ao Cromossomo X/sangue
Doenças Genéticas Ligadas ao Cromossomo X/genética
Hormônios Esteroides Gonadais/sangue
Deficiência Intelectual/sangue
Deficiência Intelectual/genética
Pregnanolona/sangue
Pregnanolona/deficiência
Pregnenolona/sangue
[Mh] Termos MeSH secundário: 17-alfa-Hidroxiprogesterona/sangue
Adolescente
Hormônio Adrenocorticotrópico/farmacologia
Síndrome Adrenogenital/sangue
Estudos de Casos e Controles
Criança
Pré-Escolar
Análise Mutacional de DNA
Estradiol/sangue
Feminino
Seres Humanos
Hidrocortisona/sangue
Progesterona/sangue
Estudos Prospectivos
Puberdade Precoce/sangue
Puberdade Precoce/genética
Valores de Referência
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Cadherins); 0 (Gonadal Steroid Hormones); 0 (PCDH19 protein, human); 04Y4D91RG0 (pregnenolone sulfate); 4G7DS2Q64Y (Progesterone); 4TI98Z838E (Estradiol); 68-96-2 (17-alpha-Hydroxyprogesterone); 73R90F7MQ8 (Pregnenolone); 9002-60-2 (Adrenocorticotropic Hormone); BXO86P3XXW (Pregnanolone); WI4X0X7BPJ (Hydrocortisone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:180107
[Lr] Data última revisão:
180107
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1111/epi.13772


  3 / 3813 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28890442
[Au] Autor:Le Moal J; Rigou A; Le Tertre A; De Crouy-Channel P; Léger J; Carel JC
[Ad] Endereço:Environmental Health DivisionSanté publique France, Saint-Maurice, France joelle.lemoal@santepubliquefrance.fr.
[Ti] Título:Marked geographic patterns in the incidence of idiopathic central precocious puberty: a nationwide study in France.
[So] Source:Eur J Endocrinol;178(1):33-41, 2018 Jan.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: Precocious puberty seems to be increasing but epidemiological data are scarce. Our objective was to improve the epidemiologic knowledge on this disease. We analyzed the national incidence and spatial trends of idiopathic central precocious puberty in France in 2011-2013 in a cross-sectional descriptive study. DESIGN: We used an indicator based on treatment reimbursements recorded in the national insurance database, in girls under the age of nine years and in boys under the age of 10 years. We considered a time lag of up to one year from the onset of puberty to first drug delivery. We tested four different predictive spatial models at the scale, selecting the model best fitting the data. We carried out semi-structured interviews with qualified hospital teams in five selected regions to investigate spatial differences in medical practices. RESULTS: The national annual incidence was 2.68 (95% CI: 2.55, 2.81) per 10 000 girls under the age of 9 years and 0.24 (95% CI: 0.21, 0.27) per 10 000 boys under the age of 10 years. Incidence rates conformed to a purely spatial heterogeneity model in girls, consistent between age groups, with a large incidence range. A similar pattern was observed for boys, with peaks in the South West and Center East. Differences in medical practices may have slightly affected incidence locally, but could not entirely explain the marked geographic pattern. CONCLUSIONS: The results suggest that the risk factors are similar for boys and girls and justify further investigations of the role of the environment.
[Mh] Termos MeSH primário: Puberdade Precoce/diagnóstico
Puberdade Precoce/epidemiologia
[Mh] Termos MeSH secundário: Criança
Pré-Escolar
Estudos Transversais
Feminino
França/epidemiologia
Seres Humanos
Incidência
Lactente
Recém-Nascido
Masculino
Fatores Sexuais
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171128
[Lr] Data última revisão:
171128
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170912
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-0379


  4 / 3813 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28973010
[Au] Autor:Lin YC; Lin CY; Chee SY; Yen HR; Tsai FJ; Chen CY; Wang CH
[Ad] Endereço:Department of Chinese Medicine, China Medical University Hospital, Taichung City, Taiwan.
[Ti] Título:Improved final predicted height with the injection of leuprolide in children with earlier puberty: A retrospective cohort study.
[So] Source:PLoS One;12(10):e0185080, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The adult height of children with early onset puberty is limited by the premature maturation of hypothalamic-pituitary-gonadal axis. To evaluate the effects of gonadotropin-releasing hormone analog (GnRHa) treatment on the final height (FH) and bone maturation rate (BMR) in girls with early puberty (EP) or idiopathic central precocious puberty (ICPP), we examined data from girls who were diagnosed with EP or ICPP and underwent GnRHa (Leuplin Depot: 3.75 mg/month) at China Medical University Hospital, in Taiwan, between 2006 and 2015. Patients were observed until the achievement of FH and divided into an "EP group" (T-ep) and "ICPP group" (T-icpp) according to the age of onset of puberty. Eighty-seven patients were enrolled (T-ep, N = 44, puberty onset at 8-10 years; T-icpp, N = 43, puberty onset before 8 years). The demographic data of girls with EP or IPP was characterized. BMR, change in predicted final height (PFH) after GnRHa treatment, target height (TH) and FH were measured. After GnRHa treatment, the study groups (T-ep: 160.24±6.18 cm, T-icpp: 158.99±5.92 cm) both had higher PFH than at initiation (T-ep: 159.83±7.19 cm, T-icpp: 158.58±5.93 cm). There was deceleration of BMR in both groups (T-ep: 0.57±0.39; T-icpp: 0.97±0.97) and a significant difference between the groups (p = 0.027). The gap in FH standard deviation scores (SDS) and TH SDS had a significant difference in T-ep (p = 0.045) but not in T-icpp. Moreover, there was no difference in the gap of PFH SDS between the 1st and final treatment in both groups. We concluded that GnRHa decelerated BMR in girls with earlier puberty. Further prospective clinical studies are warranted.
[Mh] Termos MeSH primário: Estatura/efeitos dos fármacos
Leuprolida/uso terapêutico
Puberdade Precoce/tratamento farmacológico
[Mh] Termos MeSH secundário: Criança
Feminino
Seres Humanos
Leuprolida/administração & dosagem
Estudos Retrospectivos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
EFY6W0M8TG (Leuprolide)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171004
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0185080


  5 / 3813 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28938419
[Au] Autor:Kolby N; Busch AS; Aksglaede L; Sørensen K; Petersen JH; Andersson AM; Juul A
[Ad] Endereço:Department of Growth and Reproduction, Rigshospitalet, University of Copenhagen, 2100 Copenhagen, Denmark.
[Ti] Título:Nocturnal Urinary Excretion of FSH and LH in Children and Adolescents With Normal and Early Puberty.
[So] Source:J Clin Endocrinol Metab;102(10):3830-3838, 2017 Oct 01.
[Is] ISSN:1945-7197
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Context: Clinical use of single serum gonadotropin measurements in children is limited by the pulsatile secretion of follicle-stimulating hormone (FSH) and luteinizing hormone (LH). However, first morning voided (FMV) urine may integrate the fluctuating gonadotropin serum levels. Objective: We aimed to evaluate urinary and serum gonadotropin levels according to age, sex, and pubertal stage in healthy children and to assess the clinical use of FMV urinary gonadotropins in children with disordered puberty. Design: Cross-sectional part of the COPENHAGEN Puberty Study and longitudinal study of patients. Setting: Population-based and outpatient clinic. Patients or Other Participants: Eight hundred forty-three healthy children from the COPENHAGEN Puberty Study and 25 girls evaluated for central precocious puberty (CPP). Main Outcome Measures: Clinical pubertal staging, including serum and urinary gonadotropin levels. Results: Urinary gonadotropins increased with advancing age and pubertal development and were detectable in FMV urine before physical signs of puberty. FMV urinary LH correlated strongly with basal (r = 0.871, P < 0.001) and gonadotropin-releasing hormone (GnRH)-stimulated serum LH (r = 0.82, P < 0.001). Urinary LH was superior to urinary FSH in differentiating the pubertal stage. Receiver operating curve analysis revealed that a cut-off standard deviation (SD) score of 2 for urinary LH (IU/L) gave a sensitivity of 75% and a specificity of 92% in predicting a positive GnRH stimulation test (LHmax > 5 IU/L). Urinary concentrations of LH decreased after 3 months of GnRH treatment to levels below +2 SDs. Conclusions: Urinary gonadotropin levels increased before the onset of puberty and were elevated in girls with CPP. We suggest urinary LH as an alternative noninvasive method to improve diagnosing and therapeutic management of children with disordered puberty.
[Mh] Termos MeSH primário: Ritmo Circadiano
Hormônio Foliculoestimulante/urina
Hormônio Luteinizante/urina
Puberdade Precoce/diagnóstico
Puberdade Precoce/urina
Puberdade/urina
Urinálise/métodos
[Mh] Termos MeSH secundário: Adolescente
Criança
Estudos Transversais
Feminino
Hormônio Foliculoestimulante/sangue
Seres Humanos
Estudos Longitudinais
Hormônio Luteinizante/sangue
Masculino
Puberdade/sangue
Puberdade Precoce/sangue
Sensibilidade e Especificidade
Adulto Jovem
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
9002-67-9 (Luteinizing Hormone); 9002-68-0 (Follicle Stimulating Hormone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170923
[St] Status:MEDLINE
[do] DOI:10.1210/jc.2017-01192


  6 / 3813 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28697822
[Au] Autor:Ou-Yang LX; Yang F
[Ad] Endereço:Department of Pediatrics, West China Second University Hospital, Chengdu 610041, China. 279783243@qq.com.
[Ti] Título:[Diagnostic value of baseline serum luteinizing hormone level for central precocious puberty in girls].
[So] Source:Zhongguo Dang Dai Er Ke Za Zhi;19(7):729-733, 2017 Jul.
[Is] ISSN:1008-8830
[Cp] País de publicação:China
[La] Idioma:chi
[Ab] Resumo:OBJECTIVE: To evaluate the diagnostic value of baseline serum luteinizing hormone (LH) level for central precocious puberty (CPP) in girls. METHODS: A total of 279 girls with precocious puberty were subjected to assessment of growth and development, bone age determination, baseline LH test, and follicle-stimulating hormone (FSH) test, gonadotropin-releasing hormone stimulation test, and other related examinations. Of the 279 patients, 175 were diagnosed with CPP and 104 with premature thelarche (PT). The receiver operating characteristic (ROC) curve was used to evaluate the diagnostic value of baseline LH and FSH levels and their peak levels for CPP, and the correlation between the baseline LH level and the peak LH level was analyzed. RESULTS: The CPP group had significantly higher bone age, baseline LH and FSH levels, peak LH and FSH levels, and ratio of peak LH level to peak FSH level than the PT group (P<0.01). The ROC curve proved that baseline LH level and peak LH level had good diagnostic values for CPP. Among the three bone age subgroups in the CPP group (7.0-9.0 years, 9.0-11.0 years, and >11.0 years), baseline LH level showed the best diagnostic value in the >11.0 years subgroup, with the largest area under the ROC curve. At a baseline LH level of 0.45 IU/L, the Youden index reached the peak value, and the sensitivity and specificity were 66.7% and 80% respectively, for the diagnosis of CPP. At a peak LH level of 9.935 IU/L, the Youden index reached the peak value, and the sensitivity and specificity were 74.8% and 100% respectively, for the diagnosis of CPP. The baseline LH level was positively correlated with the peak LH level (r=0.440, P<0.01). CONCLUSIONS: Baseline LH level can be used as an primary screening index for the diagnosis of CPP. It has a certain diagnostic value for CPP at different bone ages, and may be used as a monitoring index during the treatment and follow-uP.
[Mh] Termos MeSH primário: Hormônio Luteinizante/sangue
Puberdade Precoce/sangue
[Mh] Termos MeSH secundário: Adolescente
Determinação da Idade pelo Esqueleto
Criança
Feminino
Hormônio Foliculoestimulante/sangue
Seres Humanos
Puberdade Precoce/diagnóstico
Curva ROC
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
9002-67-9 (Luteinizing Hormone); 9002-68-0 (Follicle Stimulating Hormone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170713
[St] Status:MEDLINE


  7 / 3813 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28625707
[Au] Autor:Fosse-Edorh S; Rigou A; Morin S; Fezeu L; Mandereau-Bruno L; Fagot-Campagna A
[Ad] Endereço:Santé publique France, 12, rue du Val-d'Osne, 94415 Saint-Maurice cedex, France. Electronic address: sandrine.fosse@santepubliquefrance.fr.
[Ti] Título:[Algorithms based on medico-administrative data in the field of endocrine, nutritional and metabolic diseases, especially diabetes].
[Ti] Título:Algorithmes basés sur les données médico-administratives dans le champ des maladies endocriniennes, nutritionnelles et métaboliques, et en particulier du diabète..
[So] Source:Rev Epidemiol Sante Publique;65 Suppl 4:S168-S173, 2017 Oct.
[Is] ISSN:0398-7620
[Cp] País de publicação:France
[La] Idioma:fre
[Ab] Resumo:BACKGROUND: Medico-administrative databases represent a very interesting source of information in the field of endocrine, nutritional and metabolic diseases. The objective of this article is to describe the early works of the Redsiam working group in this field. METHODS: Algorithms developed in France in the field of diabetes, the treatment of dyslipidemia, precocious puberty, and bariatric surgery based on the National Inter-schema Information System on Health Insurance (SNIIRAM) data were identified and described. RESULTS: Three algorithms for identifying people with diabetes are available in France. These algorithms are based either on full insurance coverage for diabetes or on claims of diabetes treatments, or on the combination of these two methods associated with hospitalizations related to diabetes. Each of these algorithms has a different purpose, and the choice should depend on the goal of the study. Algorithms for identifying people treated for dyslipidemia or precocious puberty or who underwent bariatric surgery are also available. CONCLUSION: Early work from the Redsiam working group in the field of endocrine, nutritional and metabolic diseases produced an inventory of existing algorithms in France, linked with their goals, together with a presentation of their limitations and advantages, providing useful information for the scientific community. This work will continue with discussions about algorithms on the incidence of diabetes in children, thyroidectomy for thyroid nodules, hypothyroidism, hypoparathyroidism, and amyloidosis.
[Mh] Termos MeSH primário: Algoritmos
Bases de Dados Factuais
Diabetes Mellitus
Doenças do Sistema Endócrino
Doenças Metabólicas
Programas Nacionais de Saúde
Transtornos Nutricionais
[Mh] Termos MeSH secundário: Cirurgia Bariátrica/estatística & dados numéricos
Bases de Dados Factuais/normas
Bases de Dados Factuais/estatística & dados numéricos
Diabetes Mellitus/epidemiologia
Diabetes Mellitus/terapia
Dislipidemias/epidemiologia
Dislipidemias/terapia
Doenças do Sistema Endócrino/epidemiologia
Doenças do Sistema Endócrino/terapia
França/epidemiologia
Seres Humanos
Incidência
Sistemas Computadorizados de Registros Médicos/estatística & dados numéricos
Doenças Metabólicas/epidemiologia
Doenças Metabólicas/terapia
Programas Nacionais de Saúde/organização & administração
Programas Nacionais de Saúde/normas
Programas Nacionais de Saúde/estatística & dados numéricos
Transtornos Nutricionais/epidemiologia
Transtornos Nutricionais/terapia
Puberdade Precoce/epidemiologia
Puberdade Precoce/terapia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170620
[St] Status:MEDLINE


  8 / 3813 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28591479
[Au] Autor:Harrison VS; Oatman O; Kerrigan JF
[Ad] Endereço:Division of Endocrinology, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, U.S.A.
[Ti] Título:Hypothalamic hamartoma with epilepsy: Review of endocrine comorbidity.
[So] Source:Epilepsia;58 Suppl 2:50-59, 2017 Jun.
[Is] ISSN:1528-1167
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The most common, and usually the only, endocrine disturbance in patients with hypothalamic hamartoma (HH) and epilepsy is central precocious puberty (CPP). The mechanism for CPP associated with HH may relate to ectopic generation and pulsatile release of gonadotropin-releasing hormone (GnRH) from the HH, but this remains an unproven hypothesis. Possible regulators of GnRH release that are intrinsic to HH tissue include the following: (1) glial factors (such as transforming growth factor α[TGFα) and (2) γ-aminobutyric acid (GABA)-mediated excitation. Both are known to be present in surgically-resected HH tissue, but are present in patients with and without a history of CPP, suggesting the possibility that symptoms related to HH are directly associated with the region of anatomic attachment of the HH to the hypothalamus, which determines functional network connections, rather than to differences in HH tissue expression or pathophysiology. CPP associated with HH presents with isosexual development prior to the age of 8 years in girls and 9 years in boys. It is not uncommon for CPP with HH to present in children at an earlier age in comparison to other causes of CPP, including in infancy. Surgical resection of the HH can be effective for treating CPP, but is reserved for patients with intractable epilepsy, since GnRH agonists are widely available and effective treatment. Other endocrine disturbances with HH are rare, but can include growth hormone deficiency, hypothyroidism, and adrenal insufficiency. Diabetes insipidus is commonly encountered postoperatively, but is not observed with HH prior to surgical intervention.
[Mh] Termos MeSH primário: Epilepsia Resistente a Medicamentos/fisiopatologia
Epilepsias Parciais/fisiopatologia
Hamartoma/fisiopatologia
Doenças Hipotalâmicas/fisiopatologia
Puberdade Precoce/fisiopatologia
[Mh] Termos MeSH secundário: Criança
Pré-Escolar
Comorbidade
Epilepsia Resistente a Medicamentos/diagnóstico
Epilepsia Resistente a Medicamentos/terapia
Doenças do Sistema Endócrino/diagnóstico
Doenças do Sistema Endócrino/fisiopatologia
Doenças do Sistema Endócrino/terapia
Epilepsias Parciais/diagnóstico
Epilepsias Parciais/terapia
Feminino
Hormônio Liberador de Gonadotropina/sangue
Hamartoma/diagnóstico
Hamartoma/terapia
Hormônios Ectópicos/sangue
Seres Humanos
Doenças Hipotalâmicas/diagnóstico
Doenças Hipotalâmicas/terapia
Hipotálamo/fisiopatologia
Lactente
Masculino
Rede Nervosa/fisiopatologia
Puberdade Precoce/diagnóstico
Puberdade Precoce/terapia
Fator de Crescimento Transformador alfa/fisiologia
Ácido gama-Aminobutírico/fisiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Hormones, Ectopic); 0 (Transforming Growth Factor alpha); 33515-09-2 (Gonadotropin-Releasing Hormone); 56-12-2 (gamma-Aminobutyric Acid)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170801
[Lr] Data última revisão:
170801
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170608
[St] Status:MEDLINE
[do] DOI:10.1111/epi.13756


  9 / 3813 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28591475
[Au] Autor:Castinetti F; Brue T; Morange I; Carron R; Régis J
[Ad] Endereço:Department of Endocrinology, Assistance Publique Hôpitaux de Marseille, La Timone Hospital, Aix-Marseille University, Marseille, France.
[Ti] Título:Gamma Knife radiosurgery for hypothalamic hamartoma preserves endocrine functions.
[So] Source:Epilepsia;58 Suppl 2:72-76, 2017 Jun.
[Is] ISSN:1528-1167
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Gamma Knife radiosurgery (GK) is an effective treatment for hypothalamic hamartoma. No precise data are available on the risk of endocrine side effects of this treatment. In this study, 34 patients with hypothalamic hamartoma (HH) were followed prospectively at the Department of Endocrinology, La Timone Hospital, Marseille, France, for a mean follow-up of >2 years (mean ± standard deviation [SD] 3.6 ± 2 years). Initial pre- and post-GK radiosurgery evaluations were performed, including weight, body mass index (BMI), and a complete endocrinological workup. At diagnosis, eight patients presented with central precocious puberty at a mean age of 5.4 ± 2.4 years. At the time of GK (mean age 18.2 ± 11.1 years), two patients previously treated with surgery presented with luteinizing hormone/follicle-stimulating hormone (LH/FSH) deficiency. After GK, only one patient presented with a new thyrotropin-stimulating hormone (TSH) deficiency, 2 years after the procedure. The other pituitary axes remained normal in all but two patients (who had LH/FSH deficiency prior to GK). There was no significant difference between pre- and post-GK mean BMI (26.9 vs. 25.1 kg/m , p = 0.59). To conclude, in this group of 34 patients, GK did not induce major endocrinologic side effects reported with all the other surgical techniques in the literature. It is, thus, a safe and effective procedure in the treatment of hypothalamic hamartoma.
[Mh] Termos MeSH primário: Doenças do Sistema Endócrino/etiologia
Doenças do Sistema Endócrino/prevenção & controle
Hamartoma/cirurgia
Doenças Hipotalâmicas/cirurgia
Complicações Pós-Operatórias/etiologia
Complicações Pós-Operatórias/prevenção & controle
Radiocirurgia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Criança
Pré-Escolar
Feminino
Seguimentos
Hormônio Liberador de Gonadotropina/deficiência
Hamartoma/complicações
Seres Humanos
Doenças Hipotalâmicas/complicações
Hipotireoidismo/etiologia
Hipotireoidismo/cirurgia
Masculino
Meia-Idade
Puberdade Precoce/etiologia
Puberdade Precoce/cirurgia
Fatores de Risco
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
33515-09-2 (Gonadotropin-Releasing Hormone)
[Em] Mês de entrada:1707
[Cu] Atualização por classe:170705
[Lr] Data última revisão:
170705
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170608
[St] Status:MEDLINE
[do] DOI:10.1111/epi.13760


  10 / 3813 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28578183
[Au] Autor:Ersoy B; Kizilay D; Cayirli H; Temiz P; Gunsar C
[Ad] Endereço:Division of Pediatric Endocrinology, Celal Bayar University, School of Medicine, Manisa, Turkey.
[Ti] Título:Central Precocious Puberty Secondary to Adrenocortical Adenoma in a Female Child: Case Report and Review of the Literature.
[So] Source:J Pediatr Adolesc Gynecol;30(5):591-594, 2017 Oct.
[Is] ISSN:1873-4332
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pediatric adrenocortical tumors are rare but significant causes of virilization and peripheral precocious puberty (PPP). CASE: A 4-year-old girl presented with development of breast, pubic hair, and facial acne. Her bone age was advanced, and her gonadotropin level did not elevate in a gonadotropin-releasing hormone (GnRH) test. High levels of dehydroepiandrosterone sulfate, estradiol, and testosterone, and detection of a tumor in the left adrenal gland of the abdomen using computed tomography led to a diagnosis of PPP due to adrenal tumor. Adrenal adenoma was diagnosed with pathology after the tumor was removed. Ultrasonography detected multicystic ovaries before surgery. Although the androgen levels decreased, high estrogen levels persisted after complete tumor resection. Approximately 1 year after the surgery, the patient's breast development persisted, bone age progressed rapidly, and gonadotropin levels increased in a GnRH test. Central precocious puberty was diagnosed, and treatment with GnRH analogues was started. SUMMARY AND CONCLUSION: Adrenal adenoma might present with isosexual PPP as well as virilization in girls. The ovaries should be carefully assessed in these patients. Prolonged exposure to androgen and estrogen might cause ovarian multicysts leading to persistence of high estrogen levels and initiation of central precocious puberty.
[Mh] Termos MeSH primário: Neoplasias do Córtex Suprarrenal/complicações
Glândulas Suprarrenais/patologia
Adenoma Adrenocortical/complicações
Puberdade Precoce/etiologia
[Mh] Termos MeSH secundário: Neoplasias do Córtex Suprarrenal/cirurgia
Glândulas Suprarrenais/cirurgia
Adenoma Adrenocortical/cirurgia
Pré-Escolar
Feminino
Hormônio Liberador de Gonadotropina
Seres Humanos
Ovário/patologia
Puberdade Precoce/diagnóstico
Testosterona
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
33515-09-2 (Gonadotropin-Releasing Hormone); 3XMK78S47O (Testosterone)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171016
[Lr] Data última revisão:
171016
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170605
[St] Status:MEDLINE



página 1 de 382 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde